Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of MM-111 plus paclitaxel with or without trastuzumab in HER2-expressing gastroesophageal or gastric cancer
2012-003798-25Phase 2Terminated
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Jan 2013
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MM-111 in gastric adenocarcinoma, esophagogastric junction cancer, esophageal cancer and 1 more (2 arms), sponsored by Merrimack Pharmaceuticals. Primary endpoint: Progression-free survival. Started Jan 2013; status: terminated.
02
Drugs
MM-111
03
Conditions
gastric adenocarcinomaesophagogastric junction canceresophageal cancerdistal esophageal carcinoma
Beyond the preview
Go deeper on 2012-003798-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003798-25.